Ondine Biomedical, Inc. (OBI) AI Stock Analysis

• Market Cap: £41.73M
• Dividend Yield: N/A
• Average Volume (3M): 160.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.54
• Revenue Growth: 63.25%
• EPS Growth: 8.94%
• Country: UK
• Employees: 18
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 518,366,940
• 10 Day Avg. Volume: 119,918
• 30 Day Avg. Volume: 160,072
• PEG Ratio: 0.53
• Price to Book (P/B): 6.29
• Price to Sales (P/S): 21.10
• P/FCF Ratio: -2.79
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -4.53
• Revenue Forecast (FY): £370.23M

• Rating: 37 Underperform
• Price Target: 7.50p ▼(-14.29% Downside)

Ondine Biomedical, Inc. receives a low overall score due to significant financial performance challenges, bearish technical indicators, and unattractive valuation metrics. The company's strong revenue growth is overshadowed by its inability to achieve profitability and positive cash flow, while technical analysis suggests continued negative momentum.

Positive Factors

Revenue Growth

Sustained revenue growth near 71% indicates meaningful market traction for Ondine's aPDT technology. Over a multi-month horizon this top-line momentum supports scaling, funds further clinical/commercial investment, and validates customer demand essential for long-term commercial rollout.

High Gross Margin

A gross margin above 60% signals strong unit economics for the core photodisinfection product, giving pricing flexibility and room to absorb SG&A or R&D as the business scales. Robust gross margins are a durable foundation for eventual operating leverage and margin improvement.

Low Leverage / Conservative Capital Structure

Minimal debt and a conservative capital structure reduce solvency risk and provide strategic flexibility. For a biotech commercializing medical devices, low leverage preserves access to financing, limits fixed obligations, and helps endure extended cash burn during commercialization phases.

Negative Factors

Negative Profitability

Persistent negative EBIT and net margins indicate the company is not yet converting revenue into shareholder value. Over several months this undermines reinvestment capacity, increases financing reliance, and necessitates durable improvements in cost structure or pricing to reach sustainable profitability.

Negative Operating Cash Flow

Ongoing negative operating cash flow is a structural concern: it forces dependence on external financing to fund operations and growth. This constrains the firm's ability to scale sales, manufacturing, or clinical programs and raises execution risk if capital access tightens over the medium term.

Limited Organizational Scale

A workforce of 18 suggests limited internal capacity for commercialization, regulatory affairs, and manufacturing scale-up in complex healthcare markets. Over months this shortage can slow hospital adoption, delay reimbursement work, and increase reliance on partners, raising execution and timing risk.

Ondine Biomedical, Inc. Business Overview & Revenue Model

Company Description

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.

How the Company Makes Money

Ondine Biomedical generates revenue through the sale of its medical devices and systems, particularly the Steriwave system, to hospitals, clinics, and healthcare providers. The company may also engage in partnerships with healthcare organizations and distributors to expand its market reach and facilitate product adoption. Additionally, OBI could explore revenue streams through licensing agreements or collaborations with research institutions, enabling further development of its technologies while securing additional funding and resources.

Ondine Biomedical, Inc. Financial Statement Overview

Summary

Ondine Biomedical, Inc. demonstrates strong revenue growth, but faces significant challenges with profitability and cash flow. The low leverage is a positive aspect, but operational inefficiencies and poor cash generation hinder sustainable growth.

Income Statement

Ondine Biomedical, Inc. shows significant revenue growth of 70.94% in the latest year, indicating strong top-line expansion. However, the company struggles with profitability, evidenced by negative net profit margins and EBIT margins, which reflect ongoing operational challenges. The gross profit margin is relatively healthy at 64.47%, but the negative net income suggests high costs or inefficiencies.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio of 0.024, indicating minimal leverage and a conservative capital structure. However, the return on equity is negative, reflecting ongoing losses and challenges in generating shareholder value. The equity ratio is not explicitly calculated, but the available data suggests a moderate level of equity relative to assets.

Cash Flow

Ondine Biomedical, Inc. has a negative operating cash flow, which is a concern for sustainability. The free cash flow to net income ratio is close to 1, indicating that free cash flow is aligned with net income, albeit both are negative. The company needs to improve its cash generation to support operations and growth.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.05M	1.20M	638.00K	2.57M	1.79M
Gross Profit	1.32M	703.00K	287.00K	1.25M	649.00K
EBITDA	-18.49M	-13.79M	-18.85M	-48.36M	-14.56M
Net Income	-19.10M	-14.41M	-19.37M	-50.09M	-16.27M
Balance Sheet
Total Assets	12.82M	5.73M	16.57M	34.14M	2.63M
Cash, Cash Equivalents and Short-Term Investments	9.77M	2.98M	13.13M	30.36M	626.00K
Total Debt	168.00K	541.00K	896.00K	739.00K	31.46M
Total Liabilities	5.95M	3.65M	4.92M	4.48M	36.46M
Stockholders Equity	6.88M	2.08M	11.64M	29.66M	-33.81M
Cash Flow
Free Cash Flow	-15.50M	-13.83M	-16.66M	-12.62M	-6.43M
Operating Cash Flow	-15.49M	-13.65M	-16.34M	-12.54M	-6.33M
Investing Cash Flow	-10.00K	-177.00K	-311.00K	-77.00K	2.90M
Financing Cash Flow	21.74M	3.79M	-275.00K	41.90M	3.83M

Ondine Biomedical, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OBI, the sentiment is Negative. The current price of 8.75 is below the 20-day moving average (MA) of 9.16, below the 50-day MA of 10.75, and below the 200-day MA of 11.96, indicating a bearish trend. The MACD of -0.76 indicates Positive momentum. The RSI at 12.21 is Positive, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:OBI.

Ondine Biomedical, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FUM	52 Neutral	£7.59M	-0.63	-115.97%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SBTX	50 Neutral	£55.64M	-65.15	-11.24%	―	283.74%	78.57%
TRX	49 Neutral	£5.16M	-4.90	-5.41%	―	-20.31%	-19.35%
SAR	47 Neutral	£27.61M	-5.93	-202.14%	―	―	23.76%
OPTI	43 Neutral	£6.09M	-42.14	-2.42%	―	―	―
OBI	37 Underperform	£41.73M	-2.03	―	―	63.25%	8.94%

Ondine Biomedical, Inc. Corporate Events

Ondine Biomedical Gains Second National UK Award Shortlisting for Infection-Prevention Partnership

Ondine Biomedical and Mid Yorkshire Teaching NHS Trust have been shortlisted for the 2026 Excellence in Healthcare Partnership Awards for their collaboration using Ondine’s Steriwave nasal photodisinfection technology to reduce surgical site infections in orthopaedic patients. The partnership, which has already earned a separate national technology award nomination, demonstrated a 71% reduction in hip surgery infections and zero infections in knee surgeries over six months at the Trust’s hospitals, delivering both better patient outcomes and cost savings. The recognition underscores the growing role of non-antibiotic, resistance-free infection-prevention solutions in addressing NHS priorities such as patient safety, antimicrobial stewardship and efficiency, and comes as Steriwave adoption expands across major English hospitals and multiple clinical settings amid rising concern over antibiotic resistance and poor compliance with traditional nasal decolonisation methods.

The most recent analyst rating on (GB:OBI) stock is a Sell with a £9.50 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.

Ondine Biomedical Launches First German Hospital Trial of Steriwave with LMU Munich

Ondine Biomedical has entered a research collaboration with LMU University Hospital Munich to pilot its Steriwave nasal photodisinfection technology in ear, nose and throat patients, marking the first deployment of the platform in a German hospital and a key stepping stone into the broader EU market. The partnership, led by LMU’s LIFE Center and Laser Research Laboratory, builds on existing clinical evidence that Steriwave can significantly reduce post-operative antibiotic use, positioning the technology as a promising non-antibiotic tool against healthcare-associated infections and antimicrobial resistance, and potentially strengthening Ondine’s clinical credibility and commercial prospects in international healthcare systems focused on infection prevention.

The most recent analyst rating on (GB:OBI) stock is a Sell with a £9.50 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.

Ondine Biomedical Shortlisted for Prestigious HSJ Partnership Award

Ondine Biomedical Inc. and Mid Yorkshire Teaching NHS Trust have been shortlisted for the ‘Most Impactful Use of Technology on Clinical Practice’ award at the 2026 HSJ Partnership Awards. This recognition follows the successful implementation of Ondine’s Steriwave® nasal decolonisation technology, which significantly reduced surgical site infections and hospital costs. The technology, which offers an antibiotic-sparing alternative to traditional treatments, is gaining traction across major hospitals in England, potentially saving the NHS up to £200 million annually. The shortlisting underscores the importance of innovative solutions in addressing rising antimicrobial resistance and improving patient outcomes.

The most recent analyst rating on (GB:OBI) stock is a Sell with a £9.50 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.

Ondine Biomedical’s Steriwave Shows Promising Results in ICU Pathogen Reduction

Ondine Biomedical Inc. announced significant results from its Steriwave ICU Pilot Study at Royal Columbian Hospital, demonstrating a substantial reduction in harmful pathogens among critically ill ICU patients. The study highlights Steriwave’s potential as a non-antibiotic infection-prevention tool, showing an 80% relative risk reduction in colonization compared to controls. This innovation is particularly relevant amid rising antibiotic resistance, offering a promising alternative to traditional antibiotics and aligning with antimicrobial stewardship principles. The success of this study could enhance Ondine’s market positioning in the multi-billion-dollar ICU infection control market, potentially reducing ICU infection rates, mortality, and healthcare costs.

The most recent analyst rating on (GB:OBI) stock is a Sell with a £12.50 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.